Logo 1 Logo 2

Investigational Drug Details

Drug ID: D469
Drug Name: Triclosan
Synonyms:
Type: small molecule
DrugBank ID: DB08604
DrugBank Description: An aromatic ether that is phenol which is substituted at C-5 by a chloro group and at C-2 by a 2,4-dichlorophenoxy group. It is widely used as a preservative and antimicrobial agent in personal care products such as soaps, skin creams, toothpaste and deodorants as well as in household items such as plastic chopping boards, sports equipment and shoes.
PubChem ID: 5564
CasNo: 3380-34-5
Repositioning for NAFLD: Yes
SMILES: OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
Structure:
InChiKey: XEFQLINVKFYRCS-UHFFFAOYSA-N
Molecular Weight: 289.542
DrugBank Targets: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI; Enoyl-[acyl-carrier-protein] reductase [NADH]; Enoyl-[acyl-carrier-protein] reductase [NADH] FabI; Enoyl-[acyl-carrier-protein] reductase [NADH]; Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI; Nuclear receptor subfamily 1 group I member 2; Androgen receptor; Nuclear receptor subfamily 1 group I member 3; Peroxisome proliferator-activated receptor gamma; Thyroid peroxidase
DrugBank MoA: Triclosan is a biocidal compound with multiple targets in the cytoplasm and membrane. At lower concentrations, however, triclosan appears bacteriostatic and is seen to target bacteria mainly by inhibiting fatty acid synthesis. Triclosan binds to enoyl-acyl carrier protein reductase enzyme (ENR). This complex has increased affinity for NAD+ and forms a ternary complex. This complex is unable to participate in fatty acid synthesis, weakening the cell membrane and causing cell death. Humans do not have an ENR enzyme, and thus are not affected.
DrugBank Pharmacology:
DrugBank Indication: Triclosan is used in a variety of common household products, including soaps, mouthwashes, dish detergents, toothpastes, deodorants, and hand sanitizers. It is also used in health care settings in surgical scrubs and personnel hand washes.
Targets:
Therapeutic Category:
Clinical Trial Progress:
Latest Progress: